Atila Biosystems

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗮𝗻𝗱𝗼𝗺-𝗔𝗰𝗰𝗲𝘀𝘀 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝘁 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 At 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲, Atila BioSystems is excited to introduce a new generation of 𝗿𝗮𝗻𝗱𝗼𝗺-𝗮𝗰𝗰𝗲𝘀𝘀 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀—combining affordability, portability, automation, and fast turnaround times in a single platform. This Point of Care molecular test platform allows you to run multiple different assays simultaneously, improve turnaround times, and maximize patient management efficiency while maintaining exceptional accuracy and reliability. Our innovative solution enables laboratories, physicians, and healthcare clinics to: 🔹 Process samples immediately as they arrive 🔹 Run multiple different molecular assays simultaneously 🔹 Deliver results in under 60 minutes 🔹 Improve workflow efficiency and patient management 🔹 Expand access to high-quality molecular diagnostics 📍 𝗩𝗶𝘀𝗶𝘁 𝗔𝘁𝗶𝗹𝗮 𝗕𝗶𝗼𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟬𝟲𝟱 📅 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 | 𝗝𝘂𝗹𝘆 𝟮𝟲–𝟯𝟬 | 𝗔𝗻𝗮𝗵𝗲𝗶𝗺, 𝗖𝗮𝗹𝗶𝗳𝗼𝗿𝗻𝗶𝗮 Stop by our booth to see the platform in action and learn how Atila BioSystems is making molecular diagnostics more accessible, efficient, and affordable. #ADLM2026 #MolecularDiagnostics #PointOfCare #Diagnostics #PCR #MolecularTesting #HealthcareInnovation #AtilaBioSystems #RandomAccess

𝗝𝗼𝗶𝗻 𝗔𝘁𝗶𝗹𝗮 𝗕𝗶𝗼𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝘁 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗔𝗻𝗮𝗵𝗲𝗶𝗺, 𝗖𝗮𝗹𝗶𝗳𝗼𝗿𝗻𝗶𝗮! Visit us at 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟬𝟲𝟱 to discover our latest molecular diagnostic innovations and learn how we can help simplify your laboratory workflow. At Atila BioSystems, we offer:  • 𝟯𝟬+ 𝗲𝘅𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻-𝗳𝗿𝗲𝗲 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝘀𝘀𝗮𝘆𝘀 with 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝘂𝗻𝗱𝗲𝗿 𝟭 𝗵𝗼𝘂𝗿  • 𝗡𝗼𝗻-𝗜𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗣𝗿𝗲𝗻𝗮𝘁𝗮𝗹 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 (𝗡𝗜𝗣𝗧) solutions with Digital PCR  • 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗟𝗶𝗯𝗿𝗮𝗿𝘆 𝗣𝗿𝗲𝗽𝗮𝗿𝗮𝘁𝗶𝗼𝗻 kits for NGS applications Whether you're looking to reduce turnaround time, eliminate nucleic acid extraction, or expand your testing menu, we'd love to connect and discuss how Atila can support your laboratory. 📍 𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟬𝟲𝟱 #ADLM #ADLM2026 #AtilaBioSystems #MolecularDiagnostics #InfectiousDisease #PCR #Diagnostics #LaboratoryMedicine #NIPT #Oncology #ClinicalDiagnostics

We are excited to announce the launch of the new 𝗶𝗔𝗠𝗣® 𝗧𝗢𝗥𝗖𝗛 𝗣𝗮𝗻𝗲𝗹. Infections during pregnancy remain a major threat to reproductive health and can lead to complications such as prematurity, stillbirth, or congenital infection through vertical transmission to the fetus. The acronym “TORCH” refers to pathogens directly associated with congenital disease, including:  • 𝗧oxoplasma gondii  • 𝗢ther  • 𝗥ubella virus  • 𝗖ytomegalovirus   • 𝗛erpes simplex virus 𝗞𝗲𝘆 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀:  • Extraction-free workflow  • Simultaneous detection and differentiation of 7 targets in a single assay  • PCR lab contamination-free with BioDome® technology  • No lyophilization or reagent rehydration required  • Simplified workflow with pre-packed reagents  • Results in 60 minutes The iAMP® TORCH Panel is designed to help laboratories improve efficiency while supporting earlier and more reliable detection of infections associated with congenital diseases. #MolecularDiagnostics #isothermal #TORCH #CongenitalInfections #InfectiousDisease #AtilaBioSystems 

Atila BioSystems is heading to the 𝗔𝗦𝗖𝗖𝗣 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗶𝗻 𝗢𝗿𝗹𝗮𝗻𝗱𝗼, where we will be highlighting our partnership with Liger Medical and our shared commitment to improving cervical cancer prevention worldwide. Stop by 𝗕𝗼𝗼𝘁𝗵 #𝟭𝟰 to learn more about Atila’s innovative cervical cancer screening solutions. Through a single “𝗦𝗰𝗿𝗲𝗲𝗻, 𝗧𝗿𝗶𝗮𝗴𝗲, 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁” visit, our global solution enables providers to:  • 𝗦𝗲𝗹𝗳-𝘀𝗮𝗺𝗽𝗹𝗲 𝗳𝗼𝗿 𝗵𝗶𝗴𝗵-𝗿𝗶𝘀𝗸 𝗛𝗣𝗩 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝘂𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝘁𝗶𝗹𝗮 𝗦𝗰𝗿𝗲𝗲𝗻𝗙𝗶𝗿𝗲 𝗧𝗲𝘀𝘁  • 𝗧𝗿𝗶𝗮𝗴𝗲 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁 𝗽𝗿𝗲𝗰𝗮𝗻𝗰𝗲𝗿𝗼𝘂𝘀 𝗹𝗲𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗟𝗶𝗴𝗲𝗿 𝗜𝗿𝗶𝘀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗖𝗼𝗹𝗽𝗼𝘀𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗺𝗼𝗰𝗼𝗮𝗴𝘂𝗹𝗮𝘁𝗼𝗿 This single-visit model helps remove major barriers to cervical cancer prevention, increases treatment completion rates, and minimizes the need for follow-up visits. Together, Atila BioSystems and Liger Medical are delivering a reliable pathway toward the World Health Organization goal of eliminating cervical cancer. “𝗪𝗲’𝗿𝗲 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂 𝗲𝘃𝗲𝗿𝘆 𝘀𝘁𝗲𝗽 𝗼𝗻 𝘁𝗵𝗲 𝗛𝗣𝗩 𝗲𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗷𝗼𝘂𝗿𝗻𝗲𝘆.” #ASCCP2026 #CervicalCancer #HPV #HPVElimination #ASCCP

Excited to see global momentum building to eliminate cervical cancer and proud that Atila technology is part of the solution. A big thank you to Dr. Richard Godfrey for leading this initiative at the Rotary International to enable screening technologies to reach underserved populations. The 𝗔𝗺𝗽𝗙𝗶𝗿𝗲 𝗛𝗣𝗩 test was used in this rapid, low-cost, and scalable solution to help expand screening access in low-resource settings, where the burden of cervical cancer is highest. Innovations like AmpFire are changing what’s possible: • Enabling point-of-care testing without complex lab infrastructure • Supporting self-sampling approaches to reach more women • Delivering faster results to accelerate treatment decisions Proud that Atila BioSystems is contributing to this mission. #CervicalCancer #GlobalHealth #Diagnostics #HPV #WomensHealth https://lnkd.in/ef425xhM

Thank you BioAnalytica S.A. for representing Atila BioSystems and showcasing our solutions to the medical genetics and genomics community. We truly appreciate your continued partnership and commitment to advancing diagnostic innovation. We’re excited for what’s ahead and look forward to building on this momentum together!

Atila BioSystems is heading to 𝗘𝗨𝗥𝗢𝗚𝗜𝗡 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗩𝗶𝗲𝗻𝗻𝗮, 𝗔𝘂𝘀𝘁𝗿𝗶𝗮 — the leading international multidisciplinary HPV congress. Stop by our 𝗕𝗼𝗼𝘁𝗵 #𝟬𝟰 to learn more about Atila’s innovative cervical cancer screening solutions. We’re also excited to showcase our partnership with Liger Medical and our shared commitment to advancing cervical cancer prevention worldwide. Through a single “𝗦𝗰𝗿𝗲𝗲𝗻, 𝗧𝗿𝗶𝗮𝗴𝗲 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁” visit, our global solution enables providers to: • 𝗦𝗲𝗹𝗳-𝘀𝗮𝗺𝗽𝗹𝗲 𝗳𝗼𝗿 𝗵𝗶𝗴𝗵-𝗿𝗶𝘀𝗸 𝗛𝗣𝗩 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝘂𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝘁𝗶𝗹𝗮 𝗦𝗰𝗿𝗲𝗲𝗻𝗙𝗶𝗿𝗲 𝗧𝗲𝘀𝘁 • 𝗧𝗿𝗶𝗮𝗴𝗲 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁 𝗽𝗿𝗲𝗰𝗮𝗻𝗰𝗲𝗿𝗼𝘂𝘀 𝗹𝗲𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗟𝗶𝗴𝗲𝗿 𝗜𝗿𝗶𝘀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗖𝗼𝗹𝗽𝗼𝘀𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗺𝗼𝗰𝗼𝗮𝗴𝘂𝗹𝗮𝘁𝗼𝗿 This single-visit model helps remove major barriers to cervical cancer prevention, increases treatment completion rates, and minimizes the need for follow-up visits. Together, Atila BioSystems and Liger Medical are delivering a reliable pathway toward the World Health Organization goal of eliminating cervical cancer. “𝗪𝗲’𝗿𝗲 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂 𝗲𝘃𝗲𝗿𝘆 𝘀𝘁𝗲𝗽 𝗼𝗻 𝘁𝗵𝗲 𝗛𝗣𝗩 𝗲𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗷𝗼𝘂𝗿𝗻𝗲𝘆.” #EUROGIN2026 #HPV #CervicalCancerPrevention #GlobalHealth #WomensHealth

We are excited to announce that Atila BioSystems and Liger Medical have partnered to deliver an integrated and robust solution for screening and treating cervical pre-cancer. Through a single “𝗦𝗰𝗿𝗲𝗲𝗻, 𝗧𝗿𝗶𝗮𝗴𝗲 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁” visit, our global solution enables providers to do all the following:  • 𝗦𝗲𝗹𝗳 𝘀𝗮𝗺𝗽𝗹𝗶𝗻𝗴 𝗳𝗼𝗿 𝗛𝗶𝗴𝗵 𝗥𝗶𝘀𝗸 𝗛𝗣𝗩 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗔𝘁𝗶𝗹𝗮 𝗦𝗰𝗿𝗲𝗲𝗻𝗙𝗶𝗿𝗲 𝗧𝗲𝘀𝘁  • 𝗧𝗿𝗶𝗮𝗴𝗲 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁 𝗽𝗿𝗲𝗰𝗮𝗻𝗰𝗲𝗿𝗼𝘂𝘀 𝗹𝗲𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗟𝗶𝗴𝗲𝗿 𝗜𝗿𝗶𝘀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗖𝗼𝗹𝗽𝗼𝘀𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗺𝗼𝗰𝗼𝗮𝗴𝘂𝗹𝗮𝘁𝗼𝗿 This single‑visit model removes major barriers to cervical cancer prevention, boosts treatment completion, and minimizes the need for follow‑up visits. Together, Atila and Liger Medical deliver the most reliable pathway on the road to the WHO objective to eliminate cervical cancer. “𝗪𝗲’𝗿𝗲 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂 𝗲𝘃𝗲𝗿𝘆 𝘀𝘁𝗲𝗽 𝗼𝗻 𝘁𝗵𝗲 𝗛𝗣𝗩 𝗲𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗷𝗼𝘂𝗿𝗻𝗲𝘆.” #WorldCancerDay #CervicalCancerElimination #HPVTesting #CervicalPrecancerTreatment #AtilaBioSystems #LigerMedical 

We’re excited to announce the launch of the 𝗶𝗔𝗠𝗣® 𝗚𝗮𝘀𝘁𝗿𝗼𝗶𝗻𝘁𝗲𝘀𝘁𝗶𝗻𝗮𝗹 𝗣𝗮𝗻𝗲𝗹, a rapid real-time fluorescent iso qPCR test designed to support fast and accurate detection of gastrointestinal (GI) infections. 𝗜𝘁𝘀 𝗲𝘅𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻-𝗳𝗿𝗲𝗲 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗺𝗮𝗸𝗲𝘀 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗮𝘀 𝘀𝗶𝗺𝗽𝗹𝗲 𝗮𝘀 𝗮 𝗽𝗼𝗶𝗻𝘁-𝗼𝗳-𝗰𝗮𝗿𝗲 (𝗣𝗢𝗖) 𝗮𝘀𝘀𝗮𝘆, 𝘄𝗵𝗶𝗹𝗲 𝗿𝗲𝗺𝗮𝗶𝗻𝗶𝗻𝗴 𝗵𝗶𝗴𝗵𝗹𝘆 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗹𝗲. GI infections affect millions worldwide every year and often present with non-specific symptoms such as diarrhea, abdominal pain, nausea, and fever — making timely diagnosis critical. Delays in identifying the true pathogen can lead to complications, worsening symptoms, and increased healthcare burden. The 𝗶𝗔𝗠𝗣® 𝗚𝗮𝘀𝘁𝗿𝗼𝗶𝗻𝘁𝗲𝘀𝘁𝗶𝗻𝗮𝗹 𝗣𝗮𝗻𝗲𝗹 delivers rapid, reliable pathogen detection 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝗳𝗿𝗼𝗺 𝘀𝘁𝗼𝗼𝗹 𝘀𝗮𝗺𝗽𝗹𝗲𝘀, 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗻𝘂𝗰𝗹𝗲𝗶𝗰 𝗮𝗰𝗶𝗱 𝗲𝘅𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻, and simultaneously screens for: ✔️ 8 bacterial pathogens ✔️ 5 viral pathogens ✔️ 4 parasitic pathogens ✔️ 6 diarrheagenic E. coli/Shigella pathogens This panel is designed to aid clinicians in identifying the infectious cause of GI illness quickly and accurately, supporting informed decision-making alongside clinical, laboratory, and epidemiologic findings. We’re proud to help advance diagnostic efficiency and improve patient care in the fight against GI infections. #GIInfections #AtilaBioSystems #MolecularDiagnostics       

As the year comes to a close, we want to thank all of our partners, customers, and followers for your continued trust and support. At 𝗔𝘁𝗶𝗹𝗮 𝗕𝗶𝗼𝗦𝘆𝘀𝘁𝗲𝗺𝘀, we remain committed to making molecular testing 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗶𝗺𝗽𝗹𝗲𝗿, 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 — with 𝟰𝟬+ 𝗲𝘅𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻-𝗳𝗿𝗲𝗲 𝗮𝘀𝘀𝗮𝘆𝘀, pre-packed reagents, single-step pipetting, and ~1-hour turnaround time to streamline laboratory workflows. This year, our R&D team launched 𝟭𝟬+ 𝗻𝗲𝘄 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀, including:  • 𝗶𝗔𝗠𝗣® 𝗦𝗲𝗽𝘀𝗶𝘀 𝗣𝗮𝗻𝗲𝗹 — detects 30 pathogens + 11 AMR markers  • 𝗶𝗔𝗠𝗣® 𝗰𝗖𝗠𝗩 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗞𝗶𝘁  • 𝗦𝗶𝗰𝗸𝗹𝗲 𝗖𝗲𝗹𝗹 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗞𝗶𝘁𝘀 — real-time & digital PCR formats  • 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲𝘅 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝗣𝗖𝗥 𝗮𝘀𝘀𝗮𝘆𝘀 𝗳𝗼𝗿 𝗦𝗲𝗽𝘀𝗶𝘀 & 𝗛𝗣𝗩  • 𝗕𝗖𝗥-𝗔𝗕𝗟 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗣𝗖𝗥 𝗞𝗶𝘁  • 𝗶𝗔𝗠𝗣® 𝗘𝗕𝗩 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗞𝗶𝘁 𝗛𝗮𝗽𝗽𝘆 𝗛𝗼𝗹𝗶𝗱𝗮𝘆𝘀! Thank you for following our journey — we look forward to another year of innovation and partnership.